{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:58:38Z","timestamp":1791280718995,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00520-016-3363-3","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T04:04:12Z","timestamp":1471233852000},"page":"5007-5014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home"],"prefix":"10.1007","volume":"24","author":[{"given":"Mohamed","family":"Touati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lamarsalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Vergnen\u00e8gre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Jeannet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Daulange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Vergnen\u00e8gre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bordessoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"3363_CR1","unstructured":"National Institute of Cancer INCa 2013. Situation of cancer in France in 2012. http:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/La-situation- du-cancer-en-France-en-2012 . Accessed 13 Dec 2015"},{"key":"3363_CR2","unstructured":"National Institute of Cancer INCa 2014. Les cancers en France\u2014\u00e9dition 2014: http:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Les-cancers- en-France-Edition-2014. Accessed 31 Dec 2015"},{"key":"3363_CR3","unstructured":"National Institute of Cancer INCa 2013. Situation of cancer chemotherapy in France in 2013. http:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Situation-de-la-chimiotherapie-des-cancers-Rapport-2013 . Accessed 31 Dec 2015"},{"issue":"3 Pt 1","key":"3363_CR4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0761-8425(06)71575-3","volume":"23","author":"A Vergnen\u00e8gre","year":"2006","unstructured":"Vergnen\u00e8gre A, Decroisette C, Vincent F, et al. (2006) Analyse \u00e9conomique de l\u2019administration d\u2019une chimioth\u00e9rapie en hospitalisation \u00e0 domicile (HAD) compar\u00e9e \u00e0 l\u2019hospitalisation de jour dans les cancers bronchopulmonaires non \u00e0 petites cellules de Stade IV. Rev Mal Respir 23(3 Pt 1):255\u2013263","journal-title":"Rev Mal Respir"},{"key":"3363_CR5","doi-asserted-by":"crossref","unstructured":"A. Lassalle, P. Thomar\u00e9, C. Fronteau et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared to hospital administration: results of a prospective single-center study. Annals of Oncology Advance Access published November 16, 2015","DOI":"10.1093\/annonc\/mdv563"},{"key":"3363_CR6","unstructured":"FNEHAD, National Federation of French Hospitalization at Home Establishments. Available on http:\/\/www.fnehad.fr\/ . Accessed 1 Apr 2016"},{"key":"3363_CR7","unstructured":"Bortezomib Monograph. Available on http:\/\/www.fda.gov\/ . Accessed 31 Dec 2015"},{"issue":"5","key":"3363_CR8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki, et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440","journal-title":"Lancet Oncol"},{"issue":"9","key":"3363_CR9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, et al. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906\u2013917","journal-title":"N Engl J Med"},{"issue":"6","key":"3363_CR10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","volume":"99","author":"MV Mateos","year":"2014","unstructured":"Mateos MV, Bringhen S, Richardson PG, et al. (2014) Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica 99(6):1114\u20131122","journal-title":"Haematologica"},{"issue":"4","key":"3363_CR11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","volume":"93","author":"MV Mateos","year":"2008","unstructured":"Mateos MV, Hernandez JM, Hernandez MT, et al. (2008) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93(4):560\u2013565","journal-title":"Haematologica"},{"key":"3363_CR12","unstructured":"Order of 28 February 2012 fixing for 2012 the tariff items mentioned in I and IV of Article L. 162-22-10 of the Social Security Code and IV and V of the amended Article 33 of Law social security funding for 2004. http:\/\/www.legifrance.gouv.fr\/affichTexte.do;jsessionid=3E7798D70773D40F58B9F53F961661F6.tpdjo03v_2?cidTexte=JORFTEXT000025413804&dateTexte=&oldAction=rechJO&categorieLien=id&idJO=JORFCONT000025413457 . Accessed 31 Dec 2015"},{"key":"3363_CR13","unstructured":"Bellanger M. et al. Approaches for cost assessment and price setting in practice. HealthBASKET\u2014Health Benefits and Service Costs in Europe SP21-CT-2004-501588. France September 2005. http:\/\/www.ehma.org\/files\/WP-6-HealthBASKETSP21-CT-2004-501588_D18_France.pdf . Accessed 31 Dec 2015"},{"key":"3363_CR14","unstructured":"Methodological guide for the production of discharge in Hospital at home. Official Bulletin No. 2012\/7 bis Special Issue. http:\/\/www.sante.gouv.fr\/IMG\/pdf\/sts_20120007_0001_p000.pdf . Accessed 31 Dec 2015"},{"issue":"2","key":"3363_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejon.2009.09.003","volume":"14","author":"T Meenaghan","year":"2010","unstructured":"Meenaghan T, O\u2019Dwyer M, Hayden P, et al. (2010) Home administration of bortezomib: making a difference to myeloma patients\u2019 lives. Eur J Oncol Nurs: Off J Eur Oncol Nurs Soc 14(2):134\u2013136","journal-title":"Eur J Oncol Nurs: Off J Eur Oncol Nurs Soc"},{"key":"3363_CR16","unstructured":"ANAES, 2003. Consensus formalis\u00e9. Crit\u00e8re d\u2019\u00e9ligibilit\u00e9 des patients \u00e0 une chimioth\u00e9rapie anticanc\u00e9reuse \u00e0 domicile. http:\/\/www.has- sante.fr\/portail\/upload\/docs\/application\/pdf\/anaes_fiche_de_synth_350se_chimioth_35 1rapie-2.pdf . Accessed 31 Dec 2015"},{"issue":"3","key":"3363_CR17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00520-011-1125-9","volume":"20","author":"F Luthi","year":"2012","unstructured":"Luthi F, Fucina N, Divorne N, et al. (2012) Home care\u2014a safe and attractive alternative to inpatient administration of intensive chemotherapies. Support Care Cancer 20(3):575\u2013581","journal-title":"Support Care Cancer"},{"issue":"4","key":"3363_CR18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2354.2011.01247.x","volume":"20","author":"R Iredale","year":"2011","unstructured":"Iredale R, Hilgart J, Hayward J (2011) Patient perceptions of a mobile cancer support unit in South Wales. Eur J Cancer Care (Engl) 20(4):555\u2013560","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"7","key":"3363_CR19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00520-010-0917-7","volume":"19","author":"EH Joo","year":"2011","unstructured":"Joo EH, Rha SY, Ahn JB, et al. (2011) Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer 19(7):971\u2013978","journal-title":"Support Care Cancer"},{"issue":"5","key":"3363_CR20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1440-172X.2010.01876.x","volume":"16","author":"YM Lee","year":"2010","unstructured":"Lee YM, Hung YK, Mo FK, et al. (2010) Comparison between ambulatory infusion mode and inpatient infusion mode from the perspective of quality of life among colorectal cancer patients receiving chemotherapy. Int J Nurs Pract 16(5):508\u2013516","journal-title":"Int J Nurs Pract"},{"issue":"5","key":"3363_CR21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1043454206291349","volume":"23","author":"B Stevens","year":"2006","unstructured":"Stevens B, McKeever P, Law MP, et al. (2006) Children receiving chemotherapy at home: perceptions of children and parents. J Pediatr Oncol Nurs 23(5):276\u2013285","journal-title":"J Pediatr Oncol Nurs"},{"issue":"3","key":"3363_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pbc.20598","volume":"47","author":"B Stevens","year":"2006","unstructured":"Stevens B, Croxford R, McKeever P, Yamada J, Booth M, Daub S, et al. (2006) Hospital and home chemotherapy for children with leukemia: a randomized cross-over study. Pediatr Blood Cancer 47(3):285\u2013292","journal-title":"Pediatr Blood Cancer"},{"key":"3363_CR23","unstructured":"Conditions for the development of chemotherapy at home: economic and organizational analysis. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015- 03\/conditions_du_developpement_de_la_chimiotherapie_en_hospitalisation_a_do micile_-_synthese_et_recommandations.pdf. Accessed 1 Jan 2016. HAS (Haute Autorit\u00e9 Sant\u00e9). Conditions du d\u00e9veloppement de la chimioth\u00e9rapie en Hospitalisation \u00e0 Domicile : analyse \u00e9conomique et organisationnelle [en ligne]. Paris: HAS, janvier 2015, 28 p."},{"key":"3363_CR24","unstructured":"At home injectable chemotherapy\u2014Limousin HaH monograph via HEMATOLIM network ESCADHEM. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015- 03\/chimiotherapie_injectable_en_had_-_monographie_des_had_du_limousin_dans_le_cadre_du_reseau_dhematologie_du_li mousin_hematolim_via_le_dispositif_escadhem.pdf . (Accessed January 1, 2016). HAS (Haute Autorit\u00e9 Sant\u00e9).Chimioth\u00e9rapie injectable en HAD - Monographie des HAD du Limousin dans le cadre du r\u00e9seau d\u2019h\u00e9matologie du Limousin HEMATOLIM via le dispositif ESCADHEM"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3363-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3363-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3363-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T15:01:01Z","timestamp":1568300461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3363-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,15]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3363"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3363-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,15]]}}}